Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
---|---|---|---|---|---|---|
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 6402 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 6537 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 8796 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 8976 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 9339 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 9410 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 9921 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 11455 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 11599 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 11798 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 12116 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 12161 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 12471 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 13116 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 13675 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 13681 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 13720 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 14595 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 15029 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 15667 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 15770 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 15934 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 16736 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 17316 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 17681 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase POSITIVE ION MODE | ORNITHINE (M+H)+ | 17800 | Peak area normalized | female | Pre-diabetic | no neuropathy |